Retatrutide 40 mg Pen
Retatrutide (LY3437943) is an investigational peptide studied for activity at GIP, GLP-1 and glucagon receptors. The 77 Peptides 77Reta-40 presentation is labeled 40 mg. Published compound research does not establish the composition, purity or performance of this branded presentation.
For laboratory research use only. Not for human or veterinary use.
- Buy 2+ for $242.49 each and save 3%
- Buy 3+ for $237.49 each and save 5%
- Buy 5+ for $224.99 each and save 10%
- Buy 10+ for $212.49 each and save 15%
Direct from manufacturer to researcher
Shipping options confirmed at checkout
For laboratory research only
NEWAdvanced Laboratory Testing
HPLC Testing
Endotoxin Assay
TYMC Test
TAMC Test
Heavy Metal ScreeningCharacteristics
| Brand | 77 Peptides |
|---|---|
| Presentation | 77Reta-40 pen and box |
| Label amount | 40 mg |
| Research compound | Retatrutide (LY3437943) |
| CAS Number | 2381089-83-2 |
| Molecular Formula | C221H342N46O68 |
| Molar Mass | 4731.34 g/mol |
| Receptor targets | GIP, GLP-1 and glucagon |
| Status | Investigational; not an approved medicine |
| Batch documentation | Product-specific COA, formulation and storage conditions pending confirmation |
How does Retatrutide 40 mg Pen work?
Published research describes retatrutide as a triple-hormone-receptor agonist targeting glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon receptors. These findings describe the investigational molecule, not verified results for the 77 Peptides pen.
Handling & Safety
For laboratory research only. Not for human or veterinary use. Do not use the packaging illustration as administration, dosing or storage guidance. Obtain the product-specific safety data sheet, certificate of analysis and validated handling and storage instructions before laboratory use. Follow institutional safety procedures and wear appropriate protective equipment.
Summary
A separate 77 Peptides 40 mg pen presentation of retatrutide, distinct from the Reta vial listing. Scientific references are provided below. Availability has not yet been confirmed.
Certificate of Analysis (COA)
Resource
- NEJM — Triple–Hormone-Receptor Agonist Retatrutide for Obesity
- ClinicalTrials.gov — TRIUMPH-1 (NCT05929066)
- KEGG — Retatrutide chemical identification
All products on this site are for research and development use only. Products are not for human consumption of any kind. Neither the statements nor the products offered are intended to diagnose, treat, cure, or prevent any disease.
Peptide Research Insights
From the discoveries of 1977 to the next chapter in peptide science.
Explore research insights